Business
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene Therapy (CGT) manufacturer has adopted SteraMist ionized Hydrogen Peroxide (iHP) technology for its commercial-scale facility. This multi-staged implementation strengthens the facility’s Contamination Control Strategy (CCS) to meet the rigorous current Good Manufacturing Practices
About this update from Tomi Environmental Solutions, Inc.
[{"type":"image","alt":"TOMI Environmental Solutions, Inc.","displaySize":"","headline":null,"caption":"TOMI Environmental Solutions, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":146,"url":"https://media.zenfs.com/en/globenewswire.com/db1c98b8238c9a27e62185bc60166899"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fJWh7VCAjk6Wg2K7WDFOqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/db1c98b8238c9a27e62185bc60166899","width":300,"height":146}},"lazy":false},{"type":"text","content":"FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene Therapy (CGT) manufacturer has adopted SteraMist ionized Hydrogen Peroxide (iHP) technology for its commercial-scale facility. This multi-staged implementation strengthens the facility’s Contamination Control Strategy (CCS) to meet the rigorous current Good Manufacturing Practices (cGMP) requirements for developing novel genetic disease therapies.","length":568,"tagName":"p"},{"type":"text","content":"The client has invested in multiple SteraMist systems to facilitate surface treatment and automated room fogging, ensuring the highest standards and safety. To provide a seamless transition to commercial production, the partnership includes TOMI’s comprehensive standard operating procedure (SOP) development package and Installation and Operational Qualification (IQ/OQ) package performed by the TOMI Qualification Team.","length":421,"tagName":"p"},{"type":"text","content":""This collaboration reflects the continued adoption of SteraMist iHP technology across the biopharmaceutical sector, particularly in the rapidly evolving Cell and Gene Therapy market," said James Cherrey, TOMI’s Director of Product Compliance and Manufacturing. “As CGT manufacturers transition from development to commercial-scale production, there is an increasing need for validated, scalable contamination control solutions. This multi-stage implementation demonstrates our ability to support that progression with a comprehensive, turnkey approach that aligns with cGMP requirements and long-term operational needs.”","length":631,"tagName":"p"},{"type":"text","content":"To reset the laborator...